Unnamed: 0,title,date,stock,sentiment
1064690.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,RARE,neutral
1064691.0,Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics,2020-05-21 08:36:00-04:00,RARE,neutral
1064692.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,RARE,positive
1064693.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,RARE,neutral
1064694.0,"Stifel Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $82",2020-05-18 10:05:00-04:00,RARE,neutral
1064695.0,Ultragenyx Announces Data From Confirmatory Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia; Says 'All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use',2020-05-15 08:05:00-04:00,RARE,positive
1064696.0,Ultragenyx Reports Longer-Term Results From First 3 Cohorts Of Phase 1/2 Study Of DTX301 In Ornithine Transcarbamylase Deficiency: All 3 Patients In Cohort 3 Confirmed Responders,2020-05-13 16:03:00-04:00,RARE,neutral
1064697.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,RARE,neutral
1064698.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,RARE,neutral
1064699.0,"Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $66",2020-05-08 08:10:00-04:00,RARE,neutral
1064700.0,Ultragenyx Pharmaceuticals Sees FY20 Sales Guidance Of $125M-$140M,2020-05-06 16:24:00-04:00,RARE,neutral
1064701.0,"Ultragenyx Pharmaceutical Q1 EPS $(2.050) Misses $(1.690) Estimate, Sales $36.300M Miss $36.580M Estimate",2020-05-06 16:23:00-04:00,RARE,negative
1064702.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,RARE,positive
1064703.0,GeneTx And Ultragenyx Announce GTX-102 Granted Fast Track Designation By US FDA For Treatment Of Angelman Syndrome,2020-05-04 08:31:00-04:00,RARE,positive
1064704.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,RARE,neutral
1064705.0,"Ultragenyx Earlier Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology; Ultragenyx To Receive $200M Upfront, Including $125M In Cash And $75M Via Equity Investment",2020-04-01 08:42:00-04:00,RARE,neutral
1064706.0,"The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests",2020-04-01 07:38:00-04:00,RARE,neutral
1064707.0,"REGENXBIO, Ultragenyx Report New License Deal For Use Of NAV Technology Platform For Treatment Of Rare Metabolic Disorder; REGENXBIO To Receive $7M Upfront Payment",2020-03-31 16:07:00-04:00,RARE,negative
1064708.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,RARE,positive
1064709.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,RARE,neutral
1064710.0,"Ultragenyx, GeneTx Bio Report First Patient Dosed In KIK-AS Study Of GTX-102 For Angelman Syndrome",2020-03-16 08:42:00-04:00,RARE,neutral
1064711.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,RARE,negative
1064712.0,Ultragenyx Announces Planned Transition Of Chief Financial Officer,2020-03-03 16:20:00-05:00,RARE,neutral
1064713.0,Ultragenyx And Kyowa Kirin Announce FDA Acceptance And Priority Review Designation Of Supplemental Biologics License Application For Crysvita For Tumor-Induced Osteomalacia,2020-02-27 08:19:00-05:00,RARE,positive
1064714.0,"Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $75",2020-02-14 07:35:00-05:00,RARE,neutral
1064715.0,"Ultragenyx Pharmaceutical Q4 EPS $(1.62) Beats $(1.65) Estimate, Sales $35.593M Beat $32.15M Estimate",2020-02-13 16:02:00-05:00,RARE,neutral
1064716.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,RARE,negative
1064717.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,RARE,neutral
1064718.0,"Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $77",2020-01-17 08:31:00-05:00,RARE,negative
1064719.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,RARE,neutral
1064720.0,GeneTx And Ultragenyx Announce Investigational New Drug Application Is Now Active Active For GTX-102 In Patients with Angelman Syndrome; Enrollment In First Phase 1/2 Study Expected To Begin In 1H 2020,2020-01-15 16:02:00-05:00,RARE,positive
1064721.0,Ultragenyx and Kyowa Kirin Submit Supplemental Biologics License Application to FDA for Crysvita for Tumor-Induced Osteomalacia,2020-01-13 08:24:00-05:00,RARE,neutral
1064722.0,"Ultragenyx Sees Prelim. FY19 Sales $102M-$104M vs 100.68M Est., Sees Prelim. FY19 Crysvita Sales $86M-$88M; Sees FY20 Crysvita Sales In Ultragenyx Territories $125M-$140M Excluding EU Royalty Revenue",2020-01-13 08:24:00-05:00,RARE,neutral
1064723.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,RARE,neutral
1064724.0,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet,2020-01-10 14:41:00-05:00,RARE,positive
1064725.0,40 Stocks Moving In Friday's Mid-Day Session,2020-01-10 12:29:00-05:00,RARE,neutral
1064726.0,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump,2020-01-10 12:13:00-05:00,RARE,negative
1064727.0,Ultragenyx Pharmaceuticals shares are trading higher after the company announced positive topline cohort 3 results and improved longer-term Cohort 2 results from the Phase 1/2 study of DTX301 gene therapy.,2020-01-10 10:26:00-05:00,RARE,positive
1064728.0,"SunTrust Robinson Humphrey Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $80",2020-01-10 09:50:00-05:00,RARE,neutral
1064729.0,33 Stocks Moving in Friday's Pre-Market Session,2020-01-10 07:26:00-05:00,RARE,neutral
1064730.0,"The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx",2020-01-10 07:13:00-05:00,RARE,positive
1064731.0,Ultragenyx Pharmaceuticals shares are trading higher after the company announced positive topline cohort 3 results and improved longer-term Cohort 2 results from the Phase 1/2 study of DTX301 gene therapy.,2020-01-09 16:15:00-05:00,RARE,positive
1064732.0,Ultragenyx Announces Improved Longer-Term Cohort 2 Results From Phase 1/2 Study Of DTX301 Gene Therapy,2020-01-09 16:07:00-05:00,RARE,positive
1064733.0,Ultragenyx Announces Topline Cohort 3 Results And Improved Longer-Term Cohort 2 Results From Phase 1/2 Study of DTX301 Gene Therapy In Ornithine Transcarbamylase (OTC) Deficiency,2020-01-09 16:02:00-05:00,RARE,positive
1064734.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2020",2020-01-02 10:42:00-05:00,RARE,positive
1064735.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,RARE,neutral
1064736.0,Ultragenyx Pharmaceutical Inc Shares To Resume Trade At 9:00 a.m. EDT,2019-12-18 08:46:00-05:00,RARE,positive
1064737.0,Ultragenyx Sells Future European Royalties On Crysvita For $320M To Royalty Pharma,2019-12-18 08:37:00-05:00,RARE,neutral
1064738.0,"Ultragenyx Shares Halted, News Pending",2019-12-18 08:28:00-05:00,RARE,positive
1064739.0,8 Biotech Stocks Morgan Stanley Recommends For 2020,2019-12-17 18:27:00-05:00,RARE,positive
1064740.0,"Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $73",2019-12-17 09:23:00-05:00,RARE,negative
1064741.0,The Gene Therapy Names Moving On The Audentes Buyout Deal,2019-12-03 11:53:00-05:00,RARE,neutral
1064742.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,RARE,neutral
1064743.0,Stocks That Hit 52-Week Lows On Monday,2019-11-18 13:49:00-05:00,RARE,negative
1064744.0,Stocks That Hit 52-Week Lows On Wednesday,2019-11-13 10:50:00-05:00,RARE,negative
1064745.0,Stocks That Hit 52-Week Lows On Friday,2019-11-08 11:41:00-05:00,RARE,negative
1064746.0,"Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $45",2019-11-07 07:39:00-05:00,RARE,negative
1064747.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,RARE,negative
1064748.0,"Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $76",2019-11-06 09:08:00-05:00,RARE,negative
1064749.0,"JMP Securities Maintains Market Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $80",2019-11-06 09:01:00-05:00,RARE,positive
1064750.0,"Ultragenyx Pharmaceutical Q3 EPS $(1.96) Misses $(1.68) Estimate, Sales $25.8M Miss $28.94M Estimate",2019-11-05 16:18:00-05:00,RARE,negative
1064751.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,RARE,negative
1064752.0,Ultragenyx Announces FDA Accepts New Drug Application for UX007 for Treatment of Long-chain Fatty Acid Oxidation Disorders,2019-10-14 08:32:00-04:00,RARE,positive
1064753.0,Ultragenyx and Kyowa Kirin Announce FDA Approves Label Update for Crysvita for the Treatment of X-Linked Hypophosphatemia,2019-09-30 08:30:00-04:00,RARE,positive
1064754.0,Ultragenyx And Kyowa Kirin Announce Intent To Submit Supplemental Biologics License Application FDA For Crysvita In Tumor-Induced Osteomalacia,2019-09-10 09:07:00-04:00,RARE,neutral
1064755.0,60 Biggest Movers From Yesterday,2019-09-05 05:20:00-04:00,RARE,neutral
1064756.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-09-04 12:27:00-04:00,RARE,neutral
1064757.0,Hearing Ultragenyx Price Target Raised To New Street-High Of $85 By Leerink Analyst,2019-09-04 11:53:00-04:00,RARE,neutral
1064758.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-09-04 07:56:00-04:00,RARE,neutral
1064759.0,Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia,2019-09-04 04:01:00-04:00,RARE,positive
1064760.0,Ultragenyx Announces Partnership With GeneTx To Advance Treatment For Angelman Syndrome; Ultragenyx To Make Upfront Payment Of $20M For An Exclusive Option To Acquire GeneTx,2019-08-14 08:46:00-04:00,RARE,positive
1064761.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,RARE,neutral
1064762.0,"Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $79",2019-08-02 11:55:00-04:00,RARE,negative
1064763.0,"Wedbush Assumes Ultragenyx Pharmaceutical at Outperform, Announces $75 Price Target",2019-08-02 08:27:00-04:00,RARE,neutral
1064764.0,Ultragenyx Announces Submission Of New Drug Application To FDA For UX007 For Treatment Of Long-Chain Fatty Acid Oxidation Disorders,2019-08-01 09:11:00-04:00,RARE,neutral
1064765.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,RARE,negative
1064766.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,RARE,negative
1064767.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,RARE,positive
1064768.0,"UPDATE: Arcturus To Receive $30M In Upfront Payments, Including $6M In Cash And $24M Equity Investment At $10/Share",2019-06-19 08:33:00-04:00,RARE,neutral
1064769.0,"Ultragenyx, Arcturus Therapeutics Report Expansion Of Existing Research Collaboration, License Deal To Develop Additional Nucleic Acid Therapies for Rare Diseases",2019-06-19 08:31:00-04:00,RARE,neutral
1064770.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,RARE,positive
1064771.0,Many US-traded stocks are trading higher as recent economic signals have raised the potential for a Federal Reserve rate cut.,2019-06-07 12:31:00-04:00,RARE,negative
1064772.0,"Ultragenyx Pharmaceutical Q1 EPS $(1.82) Misses $(1.74) Estimate, Sales $18.17M Miss $18.3M Estimate",2019-05-06 16:35:00-04:00,RARE,negative
1064773.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-05-04 16:56:00-04:00,RARE,neutral
1064774.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,RARE,positive
1064775.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-18 10:51:00-04:00,RARE,negative
1064776.0,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,2019-04-17 10:31:00-04:00,RARE,negative
1064777.0,Ultragenyx Announces UX007 Granted Fast Track Designation And Rare Pediatric Disease Designation By FDA FDA For Treatment Of Long-Chain Fatty Acid Oxidation Disorders,2019-04-16 08:31:00-04:00,RARE,positive
1064778.0,"Morgan Stanley Upgrades Ultragenyx Pharmaceutical to Overweight, Raises Price Target to $83",2019-03-27 06:31:00-04:00,RARE,negative
1064779.0,"Ultragenyx Reports Approval Of Crysvita In Brazil For Treatment Of X-Linked Hypophosphatemia In Adults, Children",2019-03-26 08:32:00-04:00,RARE,positive
1064780.0,These Are Some Of The Best-Performing Leveraged ETFs Of The Year,2019-03-25 13:37:00-04:00,RARE,neutral
1064781.0,Ultragenyx  Prices 5.07M Share Public Offering of Common Stock @$60/Share,2019-02-27 04:09:00-05:00,RARE,positive
1064782.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,RARE,positive
1064783.0,Ultragenyx Pharma Reports Offering OF $250M Common Stock Offering,2019-02-25 16:42:00-05:00,RARE,neutral
1064784.0,Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal,2019-02-25 15:12:00-05:00,RARE,positive
1064785.0,Ultragenyx Announces 24-week Data From First Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy In Glycogen Storage Disease Type Ia; Response In Time To Hypoglycemia And Improved Glucose Control Maintained Or Improved In All Three Patients,2019-02-21 08:31:00-05:00,RARE,positive
1064786.0,"Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $62",2019-02-21 07:53:00-05:00,RARE,neutral
1064787.0,75 Biggest Movers From Yesterday,2019-02-21 05:12:00-05:00,RARE,neutral
1064788.0,54 Stocks Moving In Wednesday's Mid-Day Session,2019-02-20 13:13:00-05:00,RARE,neutral
1064789.0,"The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering",2019-02-20 07:34:00-05:00,RARE,negative
1064790.0,"Ultragenyx Pharmaceutical Q4 EPS $(1.73) Beats $(1.79) Estimate, Sales $16.26M Beat $14.01M Estimate",2019-02-19 16:21:00-05:00,RARE,neutral
1064791.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2019-02-15 14:00:00-05:00,RARE,neutral
1064792.0,"Ultragenyx, Kyowa Kirin Reports 64-Week Results For Crysvita From Phase 3 Study For X-Linked Hypophosphatemia: 'Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy'",2019-02-14 08:39:00-05:00,RARE,positive
1064793.0,Ultragenyx Reports Results From 1st Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy In Glycogen Storage Disease Type Ia;  Response Observed In All Three Patients And Two Patients Demonstrated Clinically Meaningful Improvement In Time To Hypoglycemia,2019-01-04 08:32:00-05:00,RARE,positive
1064794.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-01-02 12:21:00-05:00,RARE,neutral
1064795.0,Ultragenyx Pharmaceutical shares are trading lower after Raymond James downgraded the stock from Market Outperform to Market Perform.,2019-01-02 10:53:00-05:00,RARE,neutral
1064796.0,Raymond James Downgrades Ultragenyx Pharmaceutical to Market Perform,2019-01-02 07:36:00-05:00,RARE,neutral
1064797.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,RARE,neutral
1064798.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,RARE,neutral
1064799.0,Ultragenyx And Kyowa Kirin Announce Health Canada Approval Of Crysvita For The Treatment Of X–linked Hypophosphatemia In Adults And Children,2018-12-06 08:32:00-05:00,RARE,positive
1064800.0,Ultragenyx Reports Intent To Submit New Drug Application For UX007 For Treatment Of Long-Chain Fatty Acid Oxidation Disorders In Mid 2019,2018-11-14 08:31:00-05:00,RARE,neutral
1064801.0,8 Biggest Price Target Changes For Thursday,2018-11-08 09:46:00-05:00,RARE,neutral
1064802.0,"Benzinga's Top Upgrades, Downgrades For November 8, 2018",2018-11-08 09:03:00-05:00,RARE,positive
1064803.0,"Citigroup Upgrades Ultragenyx Pharmaceutical to Neutral, Raises Price Target to $54",2018-11-08 06:27:00-05:00,RARE,neutral
1064804.0,"Ultragenyx Q3 EPS $(1.74) Beats $(1.96) Estimate, Sales $11.76M Beat $11.1M Estimate",2018-11-05 16:47:00-05:00,RARE,neutral
1064805.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,RARE,neutral
1064806.0,"Credit Suisse Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $59",2018-10-29 11:57:00-04:00,RARE,positive
1064807.0,"SunTrust Robinson Humphrey Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $54",2018-10-29 11:47:00-04:00,RARE,negative
1064808.0,"Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $88",2018-10-29 10:17:00-04:00,RARE,negative
1064809.0,71 Biggest Movers From Friday,2018-10-29 05:33:00-04:00,RARE,neutral
1064810.0,56 Stocks Moving In Friday's Mid-Day Session,2018-10-26 12:49:00-04:00,RARE,neutral
1064811.0,Ultragenyx Pharma shares are trading lower after the company said it will discontinue development of its UX007 drug candidate.,2018-10-26 08:43:00-04:00,RARE,neutral
1064812.0,Ultragenyx Pharma Shares Down 14% Following Resumption,2018-10-26 08:37:00-04:00,RARE,positive
1064813.0,Ultragenyx Shares To Resume Trade At 8:30 a.m. EDT,2018-10-26 08:06:00-04:00,RARE,positive
1064814.0,Ultragenyx Says Co. On Track With Separate UX007 Program In LC-FAOD With Pre-New Drug Application Meeting Later In 2018,2018-10-26 08:04:00-04:00,RARE,neutral
1064815.0,Ultragenyx Reports Will Discontinue Development Of UX007 In Glut1 DS Indication,2018-10-26 08:03:00-04:00,RARE,neutral
1064816.0,Ultragenyx Reports Topline Results From Phase 3 Study Of UX007 In Patients With Glut1 DS With Disabling Movement Disorders: Did Not Achieve Primary Endpoint,2018-10-26 08:02:00-04:00,RARE,negative
1064817.0,REGENXBIO Reports Exclusive Global License With Ultragenyx For Treatment Of CDKL5 Deficiency Disorder Using NAV Vectors,2018-10-22 07:02:00-04:00,RARE,negative
1064818.0,Ultragenyx Reports Approval Of Mepsevii In Brazil For Treatment Of Mucopolsaccharidosis VII,2018-10-18 08:33:00-04:00,RARE,positive
1064819.0,"UPDATE: Ultragenyx Says Higher-Dose Cohort 3 Patient Enrollment To Begin In 2018, Sees Data Released Mid 2019",2018-09-27 07:08:00-04:00,RARE,neutral
1064820.0,"Ultragenyx Reports Topline Cohort 2 Results From Phase 1/2 Study Of DTX301 In Ornithine Transcarbamylase Deficiency: Normalized 1 Patient In Cohort, Responder Showed 'continued biochemical improvement and clinical stability at Week 52'",2018-09-27 07:07:00-04:00,RARE,positive
1064821.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,RARE,neutral
1064822.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,RARE,positive
1064823.0,"Stocks Which Set New 52-Week High Yesterday, September 24th",2018-09-25 09:06:00-04:00,RARE,neutral
1064824.0,"The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering",2018-09-25 08:30:00-04:00,RARE,negative
1064825.0,"Bank of America Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $94",2018-09-11 11:10:00-04:00,RARE,neutral
1064826.0,"Morgan Stanley Assumes Ultragenyx Pharmaceutical at Equal-Weight, Announces Price Target $92",2018-09-10 07:28:00-04:00,RARE,neutral
1064827.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,RARE,neutral
1064828.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,RARE,neutral
1064829.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,RARE,positive
1064830.0,10 Biggest Price Target Changes For Thursday,2018-08-30 09:58:00-04:00,RARE,neutral
1064831.0,"Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $90",2018-08-30 07:36:00-04:00,RARE,neutral
1064832.0,34 Stocks Moving In Wednesday's Mid-Day Session,2018-08-29 12:30:00-04:00,RARE,neutral
1064833.0,Ultragenyx shares are up 8.3% after the FDA accepted the company's proposal to submit a New Drug Application (NDA) for UX007 for the treatment of long-chain fatty acid oxidation disorders.,2018-08-29 10:51:00-04:00,RARE,positive
1064834.0,Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007,2018-08-29 08:31:00-04:00,RARE,positive
1064835.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,RARE,neutral
1064836.0,Ultragenyx Announces European Commission Has Approved Its Mepsevii Marketing Authorization Application,2018-08-27 16:02:00-04:00,RARE,positive
1064837.0,"Ultragenyx Pharma 8-K Shows Co. Sent Blackout Trading Restriction Notice To Its Directors, Execs Informing They Will Be Prohibited From Engaging In Certain Transactions Through Aug. 24, 2018 To Sept. 30, 2018",2018-08-22 17:00:00-04:00,RARE,positive
1064838.0,"Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $92",2018-08-06 09:01:00-04:00,RARE,negative
1064839.0,"Wedbush Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $80",2018-08-06 08:05:00-04:00,RARE,neutral
1064840.0,"Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $90",2018-08-03 09:42:00-04:00,RARE,neutral
1064841.0,"Ultragenyx Pharmaceutical Q2 EPS $(1.06) Beats $(2.09) Estimate, Sales $12.794M Beat $5.42M Estimate",2018-08-02 16:57:00-04:00,RARE,neutral
1064842.0,Ultragenyx Reports First Patient Dosed In Phase 1/2 Study Of DTX401 For Treatment Of GSDIa; FDA Granted Fast Track Designation for Gene Therapy Program,2018-07-26 08:33:00-04:00,RARE,positive
1064843.0,"Leerink Swann Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $95",2018-07-19 08:16:00-04:00,RARE,neutral
1064844.0,"EU Recommends Approval Of Novartis Kymriah, Recommends Approval Of Utlragenyx Drug For Treatment Of Sly Syndrome, Recommends Approval Of Yescarta",2018-06-29 07:50:00-04:00,RARE,positive
1064845.0,"Benzinga's Top Upgrades, Downgrades For June 21, 2018",2018-06-21 08:57:00-04:00,RARE,positive
1064846.0,"Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street",2018-06-21 08:39:00-04:00,RARE,neutral
1064847.0,"Credit Suisse Downgrades Ultragenyx Pharmaceutical to Neutral, Raises Price Target to $80",2018-06-21 07:28:00-04:00,RARE,positive
1064848.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,RARE,neutral
1064849.0,"Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs",2018-06-08 09:20:00-04:00,RARE,positive
1064850.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,RARE,neutral
1064851.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,RARE,neutral
1064852.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,RARE,positive
1064853.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,RARE,neutral
1064854.0,"Ultragenyx, Kyowa Kirin Publish Phase 2 Results Showing Crysvita Improved Outcomes In Children With X-Linked Hypophosphatemia In NEJM",2018-05-23 17:02:00-04:00,RARE,positive
1064855.0,"Ultragenyx Pharma, Kyowa Kirin Report Topline Phase 3 Study Results For Crysvita For Treatment To Oral Phosphate, Active Vitamin D In Children With X-Linked Hypophosphatemia: Met Primary Endpoint",2018-05-17 08:33:00-04:00,RARE,positive
1064856.0,"Benzinga's Top Upgrades, Downgrades For May 11, 2018",2018-05-11 09:38:00-04:00,RARE,positive
1064857.0,Barclays Upgrades Ultragenyx Pharmaceutical to Overweight,2018-05-11 07:20:00-04:00,RARE,negative
1064858.0,"Benzinga's Top Upgrades, Downgrades For May 10, 2018",2018-05-10 09:17:00-04:00,RARE,positive
1064859.0,"Goldman Sachs Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces $63 Price Target",2018-05-10 08:30:00-04:00,RARE,neutral
1064860.0,"Ultragenyx Pharmaceutical Q1 Adj. EPS $(2.03), Sales $10.677M Miss $52.86M Estimate",2018-05-07 16:50:00-04:00,RARE,negative
1064861.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,RARE,neutral
1064862.0,"Ultragenyx Reports Filing, FDA Clearance Of INDA For DTX401 For Glycogen Storage Disease Type Ia",2018-04-23 08:32:00-04:00,RARE,neutral
1064863.0,"Benzinga's Top Upgrades, Downgrades For April 18, 2018",2018-04-18 09:25:00-04:00,RARE,positive
1064864.0,SunTrust Robinson Humphrey Upgrades Ultragenyx Pharmaceutical to Buy,2018-04-18 07:03:00-04:00,RARE,neutral
1064865.0,"Ultragenyx, Kyowa Kirin Report FDA Approval Of Crysvita (Burosumab) for Treatment Of Children, Adults With X-Linked Hypophosphatemia",2018-04-17 15:22:00-04:00,RARE,positive
1064866.0,"UPDATE: BofA/Merrill On Ultragenyx Says Following FDA Approval Of Burosumab, Firm Removes 'risk assumption for US sales in our model and now est. risk-adj. 2018 sales of $74mn'; Firm Had Previously Expected Sales Of $59M",2018-04-17 15:05:00-04:00,RARE,positive
1064867.0,"Ultragenyx Shares Spike ~$0.20 Higher Over $55 Level Following Mid-Day Price Target Increase From $61 To $72 By BofA/Merrill, Buy Rating Reiterated",2018-04-17 15:04:00-04:00,RARE,positive
1064868.0,"PR Confirms Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita, Ultragenyx to Host Conference Call Today at 4:30 pm Eastern Time",2018-04-17 13:26:00-04:00,RARE,positive
1064869.0,FDA Says It Granted Approval Of Crysvita To Utlragenyx Pharmaceutical,2018-04-17 13:00:00-04:00,RARE,positive
1064870.0,REMINDER: FDA PDUFA Dates Today Include: Ultragenyx BLA  for Burosumab and Rigel Pharma for Fostamatinib,2018-04-17 07:13:00-04:00,RARE,neutral
1064871.0,"The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound",2018-04-16 12:10:00-04:00,RARE,neutral
1064872.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-13 11:38:00-04:00,RARE,neutral
1064873.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,RARE,neutral
1064874.0,"Ultragenyx Provides Topline Results And DMC Review From First Cohort Of Phase 1/2 Clinical Study Of DTX301, Says 2 of 3 Patients Didn't Show A Clinically Meaningful Change In Rate Of Ureagenesis Over 12 And 20 Weeks Respectively",2018-03-07 08:06:00-05:00,RARE,positive
1064875.0,Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization in Europe,2018-02-23 08:00:00-05:00,RARE,neutral
1064876.0,"Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises price target to $60.00",2018-02-21 09:48:00-05:00,RARE,neutral
1064877.0,"JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Lowers price target to $66.00",2018-02-21 09:09:00-05:00,RARE,negative
1064878.0,"Ultragenyx Reports Q4 EPS $(1.89) vs $(1.99) Est., Sales $2.414M vs $5K In Same Qtr. Last Year",2018-02-20 16:10:00-05:00,RARE,neutral
1064879.0,Late Tuesday Ultragenyx Announced Common Stock Offering Priced At $57/Share,2018-01-24 09:10:00-05:00,RARE,neutral
1064880.0,Ultragenyx Pharma Shares Down 7.32% After Monday Filing For $175M Common Stock Offering,2018-01-23 15:39:00-05:00,RARE,positive
1064881.0,38 Biggest Movers From Yesterday,2018-01-23 04:55:00-05:00,RARE,neutral
1064882.0,Ultragenyx Announces $175M Offering Common Stock,2018-01-22 16:15:00-05:00,RARE,neutral
1064883.0,32 Stocks Moving In Monday's Mid-Day Session,2018-01-22 12:46:00-05:00,RARE,neutral
1064884.0,Ultragenyx Shares Up 11% Following Evercore ISI Upgrade From In-Line To Outperform,2018-01-22 10:07:00-05:00,RARE,positive
1064885.0,"Credit Suisse Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces $67.00 Price Target",2018-01-17 16:55:00-05:00,RARE,positive
1064886.0,"JP Morgan Healthcare Conference Continues Today, Presenters Include: Quidel, NovoCure, Acorda, PerkinElmer, Glaukos, IDEXX, MiMedx, Community Health, Global Blood Therapeutics, and Ultragenyx",2018-01-10 09:03:00-05:00,RARE,positive
1064887.0,Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in OTC Deficiency,2018-01-07 11:08:00-05:00,RARE,positive
1064888.0,Ultragenyx Sells Priority Review Voucher To Novartis for $130M,2017-12-18 08:31:00-05:00,RARE,neutral
1064889.0,"Ultragenyx Pharma, Kyowa Hakko Kirin Report Burosumab Received Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children",2017-12-15 08:31:00-05:00,RARE,positive
1064890.0,"The Week Ahead For December 4: The Biggest Catalysts, Conferences, And Investor Events",2017-12-04 11:23:00-05:00,RARE,neutral
1064891.0,"Benzinga's Top Upgrades, Downgrades For December 4, 2017",2017-12-04 09:16:00-05:00,RARE,positive
1064892.0,Jefferies Upgrades Ultragenyx Pharmaceutical to Buy,2017-12-04 08:01:00-05:00,RARE,neutral
1064893.0,Ultragenyx Pharmaceutical Says 84% Of Patients Who Received burosumab Achieved And Maintained Serum Phosphorus Levels Above The Lower Limit of Normal,2017-12-04 07:34:00-05:00,RARE,negative
1064894.0,Ultragenyx and Kyowa Kirin Announce 'Positive' 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia,2017-12-04 07:31:00-05:00,RARE,neutral
1064895.0,FDA Decisions In November: The Month In Review,2017-12-01 14:05:00-05:00,RARE,neutral
1064896.0,"Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $80.00",2017-11-16 12:47:00-05:00,RARE,negative
1064897.0,REMINDER: Ultragenxy Pharmaceuticals Has PDUFA Date For rhGUS Today,2017-11-16 09:12:00-05:00,RARE,neutral
1064898.0,Ultragenyx Reports Completion Of Patient Dosing In First Cohort Of Phase 1/2 Study Of DTX301 Gene Therapy In OTC Deficiency,2017-11-16 08:33:00-05:00,RARE,neutral
1064899.0,"Ultragenyx Announces FDA Approval of MEPSEVII, Ultragenyx to Host Conference Call Today at 5:00pm ET",2017-11-15 13:23:00-05:00,RARE,positive
1064900.0,Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate,2017-11-15 07:36:00-05:00,RARE,positive
1064901.0,"The Week Ahead For November 13: Conferences, Earnings and IPO Events To Watch",2017-11-13 09:36:00-05:00,RARE,neutral
1064902.0,Ultragenyx Reports Q3 EPS $(1.87) vs $(1.86) Est.,2017-11-02 17:48:00-04:00,RARE,neutral
1064903.0,"Ultragenyx, Kyowa Hakko Kirin Report FDA Is Not Currently Planning To Hold AdCom Panel Meeting For Burosumab BLA",2017-11-01 08:33:00-04:00,RARE,neutral
1064904.0,Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon,2017-10-31 07:52:00-04:00,RARE,neutral
1064905.0,"Ultragenyx, Dimension Therapeutics Report Expiration Of HSR Waiting Period For Deal",2017-10-26 08:41:00-04:00,RARE,neutral
1064906.0,"Ultragenyx Reports FDA Acceptance, Priority Review Designation Of Burosumab BLA",2017-10-10 08:30:00-04:00,RARE,positive
1064907.0,"Wall Street's M&A Chatter From October 2: Kroger, ILG, Methode Electronics-Pacific Insight, Ultragenyx-Dimension",2017-10-04 08:00:00-04:00,RARE,neutral
1064908.0,Ultragenyx to Acquire Dimension Therapeutics For $6/Share In A Deal Valued At ~$151M,2017-10-03 08:30:00-04:00,RARE,positive
1064909.0,"Wall Street's M&A Chatter From October 2: CenturyLink-Level 3, Unilever-Mae Terras, Dimension-Ultragenyx",2017-10-03 07:29:00-04:00,RARE,neutral
1064910.0,"Ultragenyx Offers Comment On News Co.'s Offer For Dimension Is 'Superior Proposal': 'We are pleased' With Determination, 'We look forward to completing this transaction as quickly as possible...'",2017-10-02 09:24:00-04:00,RARE,positive
1064911.0,Dimension Therapeutics Reports Board Has Determined Ultragenyx's Offer To Buy Co. At $6/Share Constitutes A 'Superior Proposal',2017-10-02 08:01:00-04:00,RARE,positive
1064912.0,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks",2017-09-19 09:13:00-04:00,RARE,neutral
1064913.0,Dimension Therapeutics Reports Board Has Determined Ultragenyx's Offer 'Could Reasonably Be Expected to Lead to a Superior Proposal',2017-09-19 08:09:00-04:00,RARE,positive
1064914.0,UPDATE: Dimension Says It Will Review The Ultragenyx Proposal And Will Not Comment Further Until That Review Is Complete,2017-09-18 15:14:00-04:00,RARE,neutral
1064915.0,Dimension Therapeutics Press Release Confirms Receipt Of Unsolicited Offer Of $5.50/Share Cash From Ultragenyx To Acquire The Co.,2017-09-18 15:12:00-04:00,RARE,neutral
1064916.0,Dimension Therpeutics Shares Were Halted Following Announcement Of Proposal To Purchase Co. At $5.50/Share In Cash By Ultragenyx Pharma,2017-09-18 08:38:00-04:00,RARE,positive
1064917.0,The Market In 5 Minutes,2017-09-14 10:07:00-04:00,RARE,neutral
1064918.0,"Benzinga's Top Upgrades, Downgrades For September 14, 2017",2017-09-14 09:24:00-04:00,RARE,positive
1064919.0,Wedbush Upgrades Ultragenyx Pharmaceutical to Outperform,2017-09-14 07:09:00-04:00,RARE,neutral
1064920.0,UPDATE: Ultragenyx Says 'All other events were assessed as mild or moderate in severity except for a Grade 3 food allergy that was considered unrelated to burosumab treatment',2017-09-11 15:02:00-04:00,RARE,neutral
1064921.0,UPDATE: Ultragenyx Says 'All patients experienced one or more adverse events. There was one serious adverse event of a tooth abscess that was considered unrelated to burosumab treatment',2017-09-11 15:02:00-04:00,RARE,negative
1064922.0,UPDATE: Ultragenyx Says 'Burosumab increased mean serum phosphorus levels by 1.2 mg/dL into the low normal range after one week of treatment...',2017-09-11 15:02:00-04:00,RARE,neutral
1064923.0,"Ultragenyx, Kyowa Hakko Kirin Report Announcement Of Added Burosumab Data In XLH, TIO At American Society for Bone and Mineral Research Meeting",2017-09-11 15:01:00-04:00,RARE,neutral
1064924.0,"Barclays Initiates Coverage On Ultragenyx Pharmaceutical with Equal-Weight Rating, Announces $60.00 Price Target",2017-09-07 07:29:00-04:00,RARE,neutral
1064925.0,Ultragenyx Pharmaceutical and Kyowa Hakko Kirin Announce Submission Of Biologics License ApplicationWith FDA For burosumab,2017-08-24 08:31:00-04:00,RARE,neutral
1064926.0,15 Biggest Mid-Day Losers For Wednesday,2017-08-23 12:42:00-04:00,RARE,negative
1064927.0,Ultragenyx Discontinues Phase 3 GNE Myopathy Study,2017-08-23 11:22:00-04:00,RARE,neutral
1064928.0,5 Biggest Price Target Changes For Wednesday,2017-08-23 09:41:00-04:00,RARE,neutral
1064929.0,"Benzinga's Top Upgrades, Downgrades For August 23, 2017",2017-08-23 09:17:00-04:00,RARE,positive
1064930.0,18 Stocks Moving In Wednesday's Pre-Market Session,2017-08-23 08:11:00-04:00,RARE,neutral
1064931.0,SunTrust Robinson Humphrey Downgrades Ultragenyx Pharmaceutical to Hold,2017-08-23 07:17:00-04:00,RARE,neutral
1064932.0,"Ultragenyx Shares Resume Trade, Down ~11%",2017-08-22 16:25:00-04:00,RARE,positive
1064933.0,"Ultragenyx Shares Were Halted To Announce Results Of Phase 3 Study, Will Resume Trade At 4:25 p.m. EDT",2017-08-22 16:08:00-04:00,RARE,positive
1064934.0,"Ultragenyx Reports Results From Phase 3 Study Of Ace-ER In GNE Myopathy: Did Not Meet Primary, Key Secondary Endpoints",2017-08-22 16:07:00-04:00,RARE,neutral
1064935.0,"Evercore ISI Group Initiates Coverage On Ultragenyx Pharmaceutical with In-Line Rating, Announces $63.00 Price Target",2017-08-17 07:30:00-04:00,RARE,neutral
1064937.0,"Bernstein Initiates Coverage On Ultragenyx Pharmaceutical with Market Perform Rating, Announces $72.00 Price Target",2017-07-27 07:56:00-04:00,RARE,neutral
1064938.0,Ultragenyx Offers Update On KRN23: BLA Filing Planned With Current Clinical Data Package In 2H'17,2017-06-23 08:31:00-04:00,RARE,neutral
1064939.0,"Companies Holding Shareholder Meetings Today Include: Apogee, Cherokee, Citrix Systems, Kroger, Mylan, Pier 1, TripAdvisor, VBI Vaccines, Universal Display, Ultragenyx Pharma, and ZAGG",2017-06-22 09:15:00-04:00,RARE,neutral
1064940.0,Ultragenyx Pharmaceutical Receives FDA Orphan Designation for Tazemetostat,2017-06-18 21:53:00-04:00,RARE,neutral
1064941.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-06-07 08:05:00-04:00,RARE,neutral
1064942.0,"Ultragenyx Reports Recombinant Human Beta-Glucuronidase BLA, MAA Filed, Accepted for Review, Announces FDA Has Granted Priority Review Status",2017-05-23 08:31:00-04:00,RARE,positive
1064943.0,"Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics",2017-05-16 08:32:00-04:00,RARE,positive
1064944.0,Ultragenyx  Reports Q1 EPS $(1.63) vs $(1.71) Est.,2017-05-04 17:46:00-04:00,RARE,neutral
1064945.0,Ultragenyx Reports Initiation of Global Phase 3 Study of UX007 in Glut1 DS Patients,2017-04-27 08:37:00-04:00,RARE,neutral
1064946.0,15 Biggest Mid-Day Gainers For Wednesday,2017-04-19 12:33:00-04:00,RARE,neutral
1064947.0,Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data,2017-04-19 12:14:00-04:00,RARE,negative
1064948.0,7 Biggest Price Target Changes For Wednesday,2017-04-19 10:04:00-04:00,RARE,neutral
1064949.0,The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data,2017-04-19 09:52:00-04:00,RARE,positive
1064950.0,"Benzinga's Top Upgrades, Downgrades For April 19, 2017",2017-04-19 09:21:00-04:00,RARE,positive
1064951.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-04-19 08:53:00-04:00,RARE,neutral
1064952.0,"Wedbush Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $75.00",2017-04-19 08:08:00-04:00,RARE,negative
1064953.0,"H.C. Wainwright Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $72.00",2017-04-19 07:05:00-04:00,RARE,negative
1064954.0,Ultragenyx +13% Premarket; Co Announced Tuesday Phase 3 Study of KRN23 Met Primary Endpoint,2017-04-19 06:59:00-04:00,RARE,neutral
1064955.0,"Ultragenyx, Kyowa Hakko Kirin, Announce Phase 3 Study of KRN23 Met Primary Endpoint",2017-04-18 16:04:00-04:00,RARE,neutral
1064956.0,12 Biggest Mid-Day Losers For Thursday,2017-04-06 14:13:00-04:00,RARE,negative
1064957.0,7 Biggest Price Target Changes For Thursday,2017-04-06 10:21:00-04:00,RARE,neutral
1064958.0,"Benzinga's Top Upgrades, Downgrades For April 6, 2017",2017-04-06 09:28:00-04:00,RARE,positive
1064959.0,"Ultragenyx, Kyowa Kirin Report Data from Pediatric Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia",2017-04-06 08:31:00-04:00,RARE,neutral
1064960.0,"Jefferies Downgrades Ultragenyx Pharmaceutical To Hold, Lowers Price Target To $66",2017-04-06 06:33:00-04:00,RARE,negative
1064961.0,15 Biggest Mid-Day Losers For Thursday,2017-03-23 12:56:00-04:00,RARE,negative
1064962.0,5 Biggest Price Target Changes For Thursday,2017-03-23 10:48:00-04:00,RARE,neutral
1064963.0,Wedbush Lowers Ultragenyx Pharmaceutical Price Target On New Outlook,2017-03-23 09:57:00-04:00,RARE,negative
1064964.0,"Benzinga's Top Upgrades, Downgrades For March 23, 2017",2017-03-23 09:37:00-04:00,RARE,positive
1064965.0,The Market In 5 Minutes,2017-03-23 09:25:00-04:00,RARE,neutral
1064966.0,18 Stocks Moving In Thursday's Pre-Market Session,2017-03-23 08:23:00-04:00,RARE,neutral
1064967.0,PiperJaffray Downgrades Ultragenyx Pharmaceutical To Neutral,2017-03-23 07:53:00-04:00,RARE,neutral
1064968.0,"Wedbush Reiterates Outperform On Ultragenyx Pharmaceutical, Lowers Price Target To $80",2017-03-23 06:23:00-04:00,RARE,negative
1064969.0,"Ultragenyx Announces Topline Data From Phase 2 UXOO7 Study, Did Not Meet Primary Endpoint",2017-03-22 16:05:00-04:00,RARE,neutral
1064970.0,Ultragenyx Reports Q4 EPS $(1.75) vs. $(1.72) Est.,2017-02-16 16:18:00-05:00,RARE,neutral
1064971.0,"Ultragenyx, Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by EMA",2017-01-05 04:17:00-05:00,RARE,positive
1064972.0,Ultragenyx Spikes Higher on Volume,2016-11-30 13:59:00-05:00,RARE,neutral
1064973.0,"Ultragenyx Announces Positive Data from Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients, Reductions observed in frequency and total duration of major medical events",2016-11-30 08:33:00-05:00,RARE,positive
1064974.0,12 Biggest Mid-Day Losers For Monday,2016-11-14 12:44:00-05:00,RARE,negative
1064975.0,Risk Confirmed: Ultragenyx Shares Downgraded To Sell By Citi,2016-11-14 09:37:00-05:00,RARE,neutral
1064976.0,Benzinga's Top Downgrades,2016-11-14 08:57:00-05:00,RARE,positive
1064977.0,"Citigroup Downgrades Ultragenyx Pharmaceutical Inc. - Common Stock to Sell, Lowers to $64.00",2016-11-14 06:12:00-05:00,RARE,negative
1064978.0,Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union,2016-11-11 08:30:00-05:00,RARE,neutral
1064979.0,"Ultragenyx Reports Q3 EPS $(1.64) vs $(1.53) Est., $(1.03) in Same Qtr. Last Year, Sales $111K vs $1.16M Est.",2016-11-07 16:45:00-05:00,RARE,neutral
1064980.0,Ultragenyx Reports First Patient Enrolled in Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia,2016-10-26 08:32:00-04:00,RARE,neutral
1064981.0,Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23,2016-09-20 13:46:00-04:00,RARE,positive
1064982.0,UPDATE: Ultragenyx Says Will Still Conduct KRN23 Phase 3 Trial Even If Granted Accelerated Approval,2016-09-19 11:21:00-04:00,RARE,positive
1064983.0,Ultragenyx Reports Positive Phase 2 Study Data,2016-09-19 11:16:00-04:00,RARE,positive
1064984.0,On Ultragenyx Conference Call Exec Says Will Meet With FDA To Discuss Accelerated Approval Of KRN23,2016-09-19 11:09:00-04:00,RARE,positive
1064985.0,"Ultragenyx Announces Interim Data from Pediatric, Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia: Showed Substantial Reduction in Bone Disease, Improvement in Growth",2016-09-19 10:57:00-04:00,RARE,positive
1064986.0,"UPDATE: Ultragenyx Reported Interim Data at 24 Weeks from First Eight Patients Showed KRN23 Improved Serum Phosphorus Levels, Bone Metabolism Measures",2016-09-19 08:48:00-04:00,RARE,positive
1064987.0,Ultragenyx Shares Indicated Higher in Premarket as Co. Announced Sunday Morning Positive Interim Data from Phase 2 Study of KRN23 for Treatment of TIO,2016-09-19 08:45:00-04:00,RARE,positive
1064988.0,"Ultragenyx Shares Continue Higher Fri., Up 3%; Shares Up 16% Over Sept.; Seeing Unusual Buying at Oct. 21 $80 Call Contract; BZ NOTE: Activity Implies Move Up to $85.70 in Stock Price Over Next Month",2016-09-16 10:47:00-04:00,RARE,positive
1064989.0,Stocks With Three-Day Increasing Volume,2016-09-13 15:10:00-04:00,RARE,neutral
1064990.0,"Ultragenyx Reports Q2 Loss -$1.46 vs Est Loss/Share -$1.44, Rev $17K",2016-08-08 16:06:00-04:00,RARE,negative
1064991.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Bank Earnings,2016-07-15 07:57:00-04:00,RARE,neutral
1064992.0,Ultragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint,2016-07-15 07:52:00-04:00,RARE,neutral
1064993.0,"Ultragenyx Shares Trading Up Nearly 3% Following Favorable Phase 3 Results of rhGUS, UX003",2016-07-14 16:30:00-04:00,RARE,positive
1064994.0,"UPDATE: Ultragenyx Says Plans to Meet with FDA, EMA This Year to Discuss Plans to Submit Regulatory Filings in 1H'17",2016-07-14 16:08:00-04:00,RARE,neutral
1064995.0,"Ultragenyx Reports Topline Data from Phase 3 Trial of rhGUS, UX003: Met Primary Endpoint of Reduction in Urinary GAG Excretion",2016-07-14 16:07:00-04:00,RARE,negative
1064996.0,Benzinga's Top Initiations,2016-07-07 09:23:00-04:00,RARE,positive
1064997.0,"The Market In 5 Minutes: Improved Jobless Claims, A Big Food Acquisition And Pepsi's Latest Earnings",2016-07-07 09:02:00-04:00,RARE,positive
1064998.0,"Piper Jaffray Initiates Coverage on Ultragenyx Pharmaceutical at Overweight, Announces $70.00 PT",2016-07-07 07:28:00-04:00,RARE,negative
1064999.0,"Wedbush Recommending Clients Buy RARE, Says '...BTD for KRN23 supports our view that it is differentiated from standard of care with the ability to improve outcomes', Maintains Outperform",2016-06-28 11:39:00-04:00,RARE,positive
1065000.0,Benzinga's Top Initiations,2016-06-28 09:16:00-04:00,RARE,positive
1065001.0,Ultragenyx Receives Breakthrough Therapy Designation for KRN23,2016-06-28 08:32:00-04:00,RARE,neutral
1065002.0,Bank of America Initiates Coverage on Ultragenyx Pharmaceutical at Buy,2016-06-28 06:47:00-04:00,RARE,neutral
1065003.0,Chief Medical Officer Resignation Will Not Affect Ultragenyx's Catalyst-Rich Timeline,2016-06-17 15:27:00-04:00,RARE,negative
1065004.0,"Ultragenyx Pharmaceutical Chief Medical Officer Sunil Agarwal to Resign Effective August 18, 2016",2016-06-16 16:47:00-04:00,RARE,positive
1065005.0,Leerink Raises Ultragenyx Pharma's Price Target On Confidence In MPS 7 Treatment,2016-06-13 14:53:00-04:00,RARE,positive
1065006.0,"UPDATE: Takeda Pharma Will Make Up to $65M Investment in Ultragenyx, via Two Tranches",2016-06-07 07:08:00-04:00,RARE,neutral
1065007.0,"Ultragenyx Pharma, Takeda Pharma Report Collab for Development, Commercialization of Therapies for Rare Genetic Diseases",2016-06-07 07:05:00-04:00,RARE,neutral
1065008.0,Ultragenyx Reports Q1 EPS $(1.35) vs $(1.29) Est.,2016-05-09 17:24:00-04:00,RARE,neutral
1065009.0,Ultragenyx Pharmaceutical Spikes 4% Following Release Of Positive Phase 2 Data,2016-04-21 12:28:00-04:00,RARE,positive
1065010.0,"Ultragenyx Reports Postitive Interim Data For Phase 2 KRN23 Study, Reported No SAE's And Treatment Can Restore Serum Phospohorus Levels And May Have Meaningful Effect On Bone Health In Patients",2016-04-21 08:33:00-04:00,RARE,positive
1065011.0,Chardan Analyst: Amicus Therapeutics Could Be Bought For $22.50/Share,2016-04-12 09:44:00-04:00,RARE,neutral
1065012.0,More Mid-Cap Biotech M&A May Be Coming,2016-03-29 11:32:00-04:00,RARE,neutral
1065013.0,"Ultragenyx Reports Deal with Saint Louis University's Center for World Health, Medicine Research Collab to Advance Muscular Dystrophy Treatment",2016-03-23 08:31:00-04:00,RARE,neutral
1065014.0,Baird Buying Ultragenyx And BioMarin,2016-03-08 13:54:00-05:00,RARE,neutral
1065015.0,"Monday After Hours Baird Initiated RARE At Outperform, Firm Sees A Plethora Of Meaningful Value-Creating Events Manifesting In Coming Year W/ Potential To Drive Upside",2016-03-08 08:15:00-05:00,RARE,positive
1065016.0,"Baird Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces $85.00 PT",2016-03-07 16:12:00-05:00,RARE,neutral
1065017.0,Benzinga's Top Initiations,2016-02-19 09:12:00-05:00,RARE,positive
1065018.0,"Leerink Swann Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces $80.00 PT",2016-02-19 06:28:00-05:00,RARE,neutral
1065019.0,"Ultragenyx Has Multiple Catalysts This Year, Says H.C. Wainwright",2016-02-09 14:22:00-05:00,RARE,neutral
1065020.0,Benzinga's Top Initiations,2016-02-09 09:53:00-05:00,RARE,positive
1065021.0,"Credit Suisse Sees RARE Pullback As Buying Opportunity, Says Kyowa Hakko Kirin Estimates For Addressable XLH Patients Is Flawed",2016-02-09 09:06:00-05:00,RARE,positive
1065022.0,"Credit Suisse Maintains Outperform on Ultragenyx Pharmaceutical, Lowers PT to $106.00",2016-02-09 09:04:00-05:00,RARE,positive
1065023.0,"H.C. Wainwright Initiates RARE With Buy, Expects Key Milestone Achievements Tied To KRN23, rhGUS, UX007, And AceER To Drive Share Price,",2016-02-09 08:06:00-05:00,RARE,positive
1065024.0,"H.C. Wainwright Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces $104.00 PT",2016-02-09 08:03:00-05:00,RARE,neutral
1065025.0,"Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks",2016-01-21 12:16:00-05:00,RARE,positive
1065026.0,"Credit Suisse Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces $135.00 PT",2016-01-20 16:44:00-05:00,RARE,positive
1065027.0,Citigroup Upgrades Ultragenyx Pharmaceutical to Neutral,2016-01-12 06:41:00-05:00,RARE,neutral
1065028.0,Jefferies' Best Biotech Ideas For 2016 (And Beyond),2016-01-06 15:52:00-05:00,RARE,positive
1065029.0,"Canaccord Genuity Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces $126.00 PT",2015-12-21 16:23:00-05:00,RARE,neutral
1065030.0,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia,2015-12-02 08:30:00-05:00,RARE,positive
1065031.0,Ultragenyx Reports Q3 EPS $(1.03) vs. Est. $(0.87),2015-11-09 16:12:00-05:00,RARE,neutral
1065032.0,Ultragenyx Announces Update to UX007 Development Program in Glucose Transporter Type-1 Deficiency Syndrome,2015-11-06 09:01:00-05:00,RARE,neutral
1065033.0,"US Stock Futures Drop Ahead Of Earnings, Economic Data",2015-10-29 08:11:00-04:00,RARE,negative
1065034.0,"Ultragenyx Pharmaceutical, Arcturus Therapeutics Announce Research Collaboration, License Agreement",2015-10-29 05:03:00-04:00,RARE,positive
1065035.0,Ultragenyx Announces Positive Interim Data From Phase 2 Study of UX007 in Long-Chain Fatty Acid Oxidation Disorder Patients,2015-10-13 09:01:00-04:00,RARE,positive
1065036.0,Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency,2015-10-02 09:03:00-04:00,RARE,positive
1065037.0,"Monday's After-Hours Movers Led By Vascular Biogenics, Ultragenyx And Red Hat",2015-09-22 09:11:00-04:00,RARE,neutral
1065038.0,Benzinga's Top Initiations,2015-09-03 10:24:00-04:00,RARE,positive
1065039.0,Ultragenyx Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin,2015-09-01 09:02:00-04:00,RARE,negative
1065040.0,Ultragenyx Pharmaceutical Reports Q2 Loss $0.83 Vs Est Loss $0.63,2015-08-13 16:06:00-04:00,RARE,negative
1065041.0,This Week's First IPO: Global Blood Therapeutics Developing Drugs For Diseases Affecting Few,2015-08-13 09:23:00-04:00,RARE,neutral
1065042.0,"8-K from Ultragenyx Pharma Shows Amendment to Collaboration, License Deal with Nobelpharma for Supplying of Product",2015-08-13 06:10:00-04:00,RARE,neutral
1065043.0,"Ultragenyx Announces Initiation of Phase 2 Study of Recombinant Human Beta-Glucuronidase in Patients Under Five Years Old With Mucopolysaccharidosis 7, FDA Fast Tracks rhGUS Program In MPS 7",2015-08-05 09:01:00-04:00,RARE,neutral
1065044.0,"Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk",2015-07-27 08:07:00-04:00,RARE,negative
1065045.0,"Morgan Stanley Downgrades Ultragenyx Pharmaceutical to Equal-weight, Raises PT to $126.00",2015-07-27 04:24:00-04:00,RARE,neutral
1065046.0,Benzinga's Top #PreMarket Losers,2015-07-16 08:26:00-04:00,RARE,negative
1065047.0,Ultragenyx Prices 2.2M Share Offering @$120/Share,2015-07-16 04:25:00-04:00,RARE,positive
1065048.0,Ultragenyx Reports Offering Of $250M Shares Of Stock,2015-07-14 16:04:00-04:00,RARE,positive
1065049.0,Stocks Hitting 52-Week Highs,2015-07-09 10:17:00-04:00,RARE,neutral
1065050.0,Benzinga's Top Initiations,2015-07-09 09:33:00-04:00,RARE,positive
1065051.0,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia,2015-07-09 09:01:00-04:00,RARE,positive
1065052.0,"JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue",2015-07-09 08:49:00-04:00,RARE,neutral
1065053.0,"JMP Securities Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces $119.00 PT",2015-07-09 07:00:00-04:00,RARE,positive
1065054.0,Ultragenyx Names Daniel Welch Chair,2015-06-25 09:00:00-04:00,RARE,neutral
1065055.0,Ultragenyx Names Jayson Dallas Chief Commercial Officer,2015-06-22 09:00:00-04:00,RARE,neutral
1065056.0,Ultragenyx Finalizes Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7,2015-06-08 09:01:00-04:00,RARE,neutral
1065057.0,"Ultragenyx Reports Positive 16-Week Interim Data from Pediatric Phase 2 Study of KRN23: No Serious Adverse Events Reported, Sees Potential Conditional Approval Pathway in Europe",2015-06-02 07:03:00-04:00,RARE,positive
1065058.0,Ultragenyx Reports First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy,2015-05-28 09:01:00-04:00,RARE,neutral
1065059.0,Ultragenyx Pharma Reports Q1 Loss $0.63 Vs Est Loss $0.54,2015-05-11 16:37:00-04:00,RARE,negative
1065060.0,UltraGenyx Announces Wins Added Orphan Drug Designation for Triheptanoin,2015-04-23 09:03:00-04:00,RARE,positive
1065061.0,Ultragenyx Offers Positive Data from Investigator-Sponsored Trial of Triheptanoin in Glucose Transporter Type-1 Deficiency,2015-04-22 07:33:00-04:00,RARE,positive
1065062.0,Ultragenyx Reports Positive Data From Investigator-Sponsored Trial of Triheptanoin in Glucose Transporter Type-1 Deficiency Syndrome,2015-04-22 07:31:00-04:00,RARE,positive
1065063.0,16 Biotech Catalysts SunTrust Is Tracking,2015-04-06 19:38:00-04:00,RARE,neutral
1065064.0,"Wedbush Initiates Coverage on Ultragenyx Pharmaceutical at Outperform, Announces $74.00 PT",2015-03-31 17:36:00-04:00,RARE,neutral
1065065.0,UPDATE: MLV & Co Initiates Coverage On Ultragenyx Pharmaceutical On Positive Outlook,2015-03-31 07:47:00-04:00,RARE,positive
1065066.0,"MLV & Co Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces $79.00 PT",2015-03-30 16:40:00-04:00,RARE,neutral
1065067.0,Ultragenyx Reports Q4 EPS -$0.52 Vs Est -$0.53,2015-03-25 16:06:00-04:00,RARE,neutral
1065068.0,CRT Capital Initiates Coverage On Ultragenyx Pharmaceutical,2015-03-25 14:00:00-04:00,RARE,neutral
1065069.0,"CRT Capital Initiates Coverage on Ultragenyx Pharmaceutical at Buy, Announces $90.00 PT",2015-03-24 16:51:00-04:00,RARE,neutral
1065070.0,Ultragenyx Offers Presentation of Disease Burden Data in Adult Patients with X-Linked Hypophosphatemia,2015-03-09 09:00:00-04:00,RARE,negative
1065071.0,Ultragenyx Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7,2015-02-10 16:32:00-05:00,RARE,positive
1065072.0,Ultragenyx Prices 3M Shares at $54/Share,2015-02-04 19:10:00-05:00,RARE,positive
1065073.0,Ultragenyx Announces $125M Proposed Public Offering of Common Stock,2015-02-03 16:36:00-05:00,RARE,neutral
1065074.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,RARE,neutral
1065075.0,Ultragenyx Announces Intent to File For Conditional Approval In Europe For Sialic Acid Extended-Release Tablets,2015-01-12 09:09:00-05:00,RARE,positive
1065076.0,Wednesday's After-Hours Movers,2015-01-07 17:49:00-05:00,RARE,neutral
1065077.0,Ultragenyx Reports License of IP Related to Treatment for Huntingon's Disease Using Triheptanoin,2015-01-07 16:07:00-05:00,RARE,neutral
1065078.0,Ultragenyx Initiates New Development Program Studying KRN23 for the Treatment of Tumor-Induced Osteomalacia,2015-01-06 09:02:00-05:00,RARE,neutral
1065079.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,RARE,positive
1065080.0,Mid-Morning Market Update: Markets Open Higher; BC Partners Group To Acquire PetSmart For $83/Share,2014-12-15 10:23:00-05:00,RARE,neutral
1065081.0,Ultragenyx Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase,2014-12-15 09:10:00-05:00,RARE,neutral
1065082.0,Ultragenyx  Reports Q3 EPS of $(0.50) vs $(0.46) Est,2014-11-10 09:00:00-05:00,RARE,neutral
1065083.0,Ultragenyx Wins EU Orphan Drug Designation for KRN23 for Treatment of X-Linked Hypophosphatemia,2014-10-30 09:00:00-04:00,RARE,positive
1065084.0,Ultragenyx Announces Orphan Drug Designation for Triheptanoin for Treatment of Glucose Transporter Type-1 Deficiency Syndrome,2014-10-27 09:01:00-04:00,RARE,neutral
1065085.0,Ultragenyx Pharma Offers Interim Data from Phase 3 Extension Study of Sialic Acid ER at Int'l Congress of World Muscle Safety,2014-10-13 09:03:00-04:00,RARE,positive
1065086.0,Benzinga's Top Initiations,2014-09-23 08:32:00-04:00,RARE,positive
1065087.0,Jefferies Initiates Ultragenyx Pharmaceutical At Buy,2014-09-23 07:33:00-04:00,RARE,neutral
1065088.0,"Jefferies Initiates Coverage on Ultragenyx  at Buy, Announces $74.00 PT",2014-09-23 06:05:00-04:00,RARE,neutral
1065089.0,3 Partnerships Pushing The Pharmaceutical Sector Forward,2014-09-22 12:59:00-04:00,RARE,neutral
1065090.0,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia,2014-09-15 09:02:00-04:00,RARE,positive
1065091.0,Ultragenyx Offers Positive Interim Data from Phase 1/2 Study of Recombinant Human Beta-Glucuronidase,2014-09-03 09:08:00-04:00,RARE,positive
1065092.0,Ultragenyx  Reports Q2 EPS of $(0.45) vs $(0.42) Est,2014-08-11 09:04:00-04:00,RARE,neutral
1065093.0,"Baird Initiates Coverage on Ultragenyx  at Outperform, Announces $64.00 PT",2014-07-15 18:13:00-04:00,RARE,neutral
1065094.0,"Ultragenyx Announces Closing of ~2.3M Share Offering at $40, Net Proceeds ~$60.2M",2014-07-14 13:33:00-04:00,RARE,positive
1065095.0,US Stock Futures Flat; All Eyes On Fed Minutes,2014-07-09 07:40:00-04:00,RARE,neutral
1065096.0,Ultragenyx Announces Prices 2.017M Share Offering @$40.00/Share,2014-07-09 05:19:00-04:00,RARE,positive
1065097.0,Ultragenyx Announces Offering of ~2.017M Shares of Common Stock,2014-07-07 16:30:00-04:00,RARE,positive
1065098.0,Ultragenyx Announces Initiation Of A Phase 2 Study of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU,2014-07-01 09:04:00-04:00,RARE,neutral
1065099.0,Ultragenyx Announces Results From Phase 1/2 Study Involving KRN23 In X-Linked Hypophosphatemia In Adults,2014-06-24 12:01:00-04:00,RARE,neutral
1065100.0,Ultragenyx  Reports Q1 EPS of $(0.85) Which May Not Compare $(0.37) Est,2014-05-12 09:01:00-04:00,RARE,neutral
1065101.0,"Ultragenyx Exec at Future Leaders in the Biotech Industry Conference: Expecting FY14 Operating Loss Higher Than 2013, Sees Existing Cash Funding Operations Into 2016",2014-03-28 14:05:00-04:00,RARE,negative
1065102.0,Ultragenyx Reports Prelim. Data from Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7,2014-03-27 09:05:00-04:00,RARE,neutral
1065103.0,UPDATE: Morgan Stanley Initiates Coverage on Ultragenyx Pharmaceutical on Growing Orphan Drug Pipeline,2014-02-25 08:47:00-05:00,RARE,positive
1065104.0,Benzinga's Top Initiations,2014-02-25 07:26:00-05:00,RARE,positive
1065105.0,"Canaccord Genuity Initiates Coverage on Ultragenyx  at Buy, Announces $85.00 PT",2014-02-25 06:59:00-05:00,RARE,neutral
1065106.0,"JP Morgan Initiates Coverage on Ultragenyx  at Overweight, Announces $66.00 PT",2014-02-25 06:58:00-05:00,RARE,neutral
1065107.0,"Morgan Stanley Initiates Coverage on Ultragenyx  at Overweight, Announces $81.00 PT",2014-02-25 06:46:00-05:00,RARE,negative
1065108.0,"Six IPOs Hit Wall Street on Friday: CARA, TRVN, RARE, NWHM, SNOW, MBUU",2014-02-03 18:59:00-05:00,RARE,neutral
1065109.0,UPDATE: Ultragenyx Shares Now Over $47.50 Level,2014-01-31 10:27:00-05:00,RARE,positive
1065110.0,"Shares of Ultragenyx Pharma Open for Trade Around $45.30, Priced at $21/Share",2014-01-31 10:25:00-05:00,RARE,positive
1065111.0,Ultragenyx Prices 5.76M Share IPO at $21/Share,2014-01-30 22:53:00-05:00,RARE,positive
1065112.0,Ultragenyx Raises IPO Size to 4.8M Shares at $19-$20/Share,2014-01-30 06:25:00-05:00,RARE,positive
